The morbidity and mortality associated with diabetic complications impose a huge socioeconomic burden worldwide. Therefore, the ultimate goal of managing diabetes mellitus (DM) is to lower the risk of macrovascular complications and highly morbid microvascular complications such as diabetic nephropathy (DN) and diabetic retinopathy (DR). Potential benefits of incretin-based therapies such as glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors on the diabetic macrovascular complications have been recently suggested, owing to their pleiotropic effects on multiple organ systems. However, studies primarily investigating the role of these therapies in diabetic microvascular complications are rare. Nevertheless, preclinical and limited clinical data suggest the potential protective effect of incretin-based agents against DN and DR via their anti-inflammatory, antioxidative, and antiapoptotic properties. Evidence also suggests that these incretin-dependent and independent beneficial effects are not necessarily associated with the glucose-lowering properties of GLP-1 RAs and DPP-4 inhibitors. Hence, in this review, we revisit the preclinical and clinical evidence of incretin-based therapy for DR and DN, the two most common, morbid complications in individuals with DM. In addition, the review discusses a few recent studies raising concerns of aggravating DR with the use of incretin-based therapies.

Citations

Citations to this article as recorded by  

• Efficacy and Safety of the Utilization of Dipeptidyl Peptidase IV Inhibitors in Diabetic Patients with Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials
  Moeber Mahzari, Muhannad Alqirnas, Moustafa Alhamadh, Faisal Alrasheed, Abdulrahman Alhabeeb, Wedad Al Madani, Hussain Aldera
  Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 1425.     CrossRef
• Anti-Inflammatory Effects of GLP-1R Activation in the Retina
  Alessandra Puddu, Davide Maggi
  International Journal of Molecular Sciences.2022; 23(20): 12428.     CrossRef
• Diabetes and Its Complications: Therapies Available, Anticipated and Aspired
  Anu Grover, Komal Sharma, Suresh Gautam, Srishti Gautam, Monica Gulati, Sachin Kumar Singh
  Current Diabetes Reviews.2021; 17(4): 397.     CrossRef
• SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
  Christopher El Mouhayyar, Ruba Riachy, Abir Bou Khalil, Asaad Eid, Sami Azar
  International Journal of Endocrinology.2020; 2020: 1.     CrossRef
• Novel therapeutic agents for the treatment of diabetic kidney disease
  Rachel E. Hartman, P.S.S. Rao, Mariann D. Churchwell, Susan J. Lewis
  Expert Opinion on Investigational Drugs.2020; 29(11): 1277.     CrossRef
• Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors
  Minyoung Lee, Jiyu Sun, Minkyung Han, Yongin Cho, Ji-Yeon Lee, Chung Mo Nam, Eun Seok Kang
  Diabetes Care.2019; 42(11): 2057.     CrossRef
• Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
  Jae Hyun Bae, Sunhee Kim, Eun-Gee Park, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim
  Endocrinology and Metabolism.2019; 34(1): 80.     CrossRef
• Serum adipocytokines are associated with microalbuminuria in patients with type 1 diabetes and incipient chronic complications
  Tomislav Bulum, Marijana Vučić Lovrenčić, Martina Tomić, Sandra Vučković-Rebrina, Vinko Roso, Branko Kolarić, Vladimir Vuksan, Lea Duvnjak
  Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2019; 13(1): 496.     CrossRef
• Protective Effects of Incretin Against Age-Related Diseases
  Di Zhang, Mingzhu Ma, Yueze Liu
  Current Drug Delivery.2019; 16(9): 793.     CrossRef
• The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin
  Annayya R. Aroor, Camila Manrique-Acevedo, Vincent G. DeMarco
  Cardiovascular Diabetology.2018;[Epub]     CrossRef